Assessment of efficacy of lithium in prevention of peripheral neuropathy

Randomized double blind placebo controlled study of oral lithium for prevention of chemotherapy induce peripheral neuropathy in breast cancer patients under treatment by Taxans and Platinium base medicines

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160813029327N10

Enrollment

Registered

2018-05-16

Start date

2018-04-29

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induce peripheral neuropathy.

Interventions

Intervention 1: Intervention group: Patients in this group will receive 300 mg tablet of lithium, one day before every chemotherapy cycle up to 5 days, each day one tablet.( 5 tablets in each cycle).

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Women with breast cancer between 18 to 60 years old

Exclusion criteria

Exclusion criteria: Dissatisfaction of patients to participate in the study Pregnant or planning for pregnancy and nursing mothers Patients with peripheral nerves disorders, renal disorders, thyroid disorders, cardiovascular disorders, diabetes, bipolar

Design outcomes

Primary

Measure	Time frame
1) Comparison of EMG_NCV between the medicine group and placebo group 2) Conclusion of scoring of peripheral neuropathy. Timepoint: Just before starting chemotherapy, 3 months after starting chemotherapy, 6 months later and 1 year later, EMG_NCV and scoring of peripheral neuropathy will be taken from the patients. Method of measurement: Electro Myography_Nerve Cunduction Velocity.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mehdi Rajabi

Islamic Azad University

mehdirj@aol.co.uk+98 21 6393 5258

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 20, 2026